29 Vascular disease - Milton Keynes Formulary

• Home
• Chapters
  • 1. Gastro-Intestinal System
  • 2. Cardiovascular system
  • 3. Respiratory System
  • 4. Nervous System
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary-tract Disorders
  • 8. Immune System and Malignant Disease
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Diseases
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological Products and Vaccines
  • 15. Anaesthesia
  • 16 Wound Management
  • 17. Miscellaneous Preparations
• Drugs
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
• MK Prescribing Advisory Group (MKPAG)
  • Application Forms
  • MKPAG Ratified Minutes
  • MKPAG Meeting Dates
  • Terms of Reference (ToR)
  • M&TC Minutes
• NICE Adherence Checklist
• GP Prescribing Group
  • Terms of reference
  • Minutes
  • Archived Minutes
• Shared Care Guidelines
• Local & National General Prescribing Information
  • 1. Financial and clinical responsibility for prescribing non-formulary drugs
  • 2. Repeat Prescribing Code of Practice
  • 3. When not to prescribe generically
  • 4. MK CCG Commissioning Policies
  • 5. Borderline Substances (ACBS)
  • 6. Selective List Scheme (SLS)
  • 7. Overseas visitors
  • 8. Travelling abroad
  • 9. Liquid Specials
  • 10. SPS Drug Monitoring Document Oct 2017
  • 11. Medication Information in Practices-November 2017
  • 12. Drugs That Prolong QT Interval
  • 13 Consultation Letter to Schools Nurseries-June 2017
  • 14 Letter to parents re changes in prescribing
  • 15. Self-Care Medicine List
• Biosimilar Position Statement
• Unlicensed Medicines
• Copyright Notice
• Patient Information Leaflets (New)
• About the Formulary Local Decisions
  • About the Joint Formulary
  • Format of the Formulary and Traffic Light Classification
• Newsletters
• Useful Links
• Contact Us

2.9 Vascular disease

Traffic light status (TLS) explained:

• Green: Routine prescribing within licensed indication
• Amber 1: specialist recommendation followed by GP initiation and continuation
• Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
• Amber 3: specialist initiation and stabilisation followed by GP continuation
• Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
• Red: Hospital or specialist prescribing only
• Double Red: These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.

Peripheral vascular disease

5HT₂ Receptor Antagonists

Naftidrofuryl Oxalate (Amber 1)

• Capsules 100mg  

Note:

• Use as per NICE TA223:Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011)

2.9.1 Vein malformations

Sclerosants

Sodium Tetradecyl Sulfate (Fibro-Vein)

• Solution for injection 2mg per 1mL -  0.2%  (5mL vial) 
• Solution for injection 5mg per 1mL - 0.5% (2mL amp)
• Solution for injection 10mg per 1mL - 1% (2mL amp)
• Solution for injection 30mg per 1mL - 3% (2mL amp, 5mL vial)

Return to Chapter: 2. Cardiovascular system

Last updated by: Dupe Fagbenro on 12-12-2018 15:26